PXD101
Term · Oncology and biomedicine · MLC-T-ONC-007106
A drug used to treat adults with peripheral T-cell lymphoma that has come back or has not gotten better with other treatment. It is also being studied in the treatment of other types of cancer. PXD101 blocks certain enzymes needed for cell division and may kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow and may help make cancer cells easier to kill with other anticancer drugs. It is a type of histone deacetylase inhibitor, a type of antiangiogenesis agent, and a type of chemosensitizer. Also called Beleodaq and belinostat.
| Identifier | MLC-T-ONC-007106 |
|---|---|
| Field | Oncology and biomedicine |
| Expansions | Beleodaq; belinostat |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-007106",
"term": "PXD101",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat adults with peripheral T-cell lymphoma that has come back or has not gotten better with other treatment. It is also being studied in the treatment of other types of cancer. PXD101 blocks certain enzymes needed for cell division and may kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow and may help make cancer cells easier to kill with other anticancer drugs. It is a type of histone deacetylase inhibitor, a type of antiangiogenesis agent, and a type of chemosensitizer. Also called Beleodaq and belinostat.",
"expansions": [
"Beleodaq",
"belinostat"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/pxd101/"
}
Record 13,901 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.